Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating activities:
Net income	$ 2,158	$ 1,717
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	494	534
Amortization of right of use lease assets	95	91
Accretion related to acquisition, net	11	11
Amortization of subordinated debt issuance costs	32	33
Gain on redemption and retirement of subordinated notes	(656)	0
Provision for credit losses	717	80
Loss on sale of securities, net	176	0
Net amortization of securities	69	154
(Increase) decrease in loans held for sale, net	(111)	470
Net loss (gain) on write-down/sale of repossessed assets	84	(22)
Income from bank owned life insurance	(282)	(265)
Stock compensation expense	110	75
Decrease (increase) in other assets	296	(147)
(Decrease) increase in accrued expenses and other liabilities	(1,028)	1,047
Net cash provided by operating activities	2,165	3,778
Investing activities:
Purchases of available-for-sale securities	(5,886)	(1,230)
Cash used in purchases of restricted securities, net	(4)	(63)
Proceeds from maturities of available-for-sale securities	400	570
Proceeds from sales of available-for-sale securities	1,394	450
Paydowns on available-for-sale securities	3,118	4,197
Net (increase) decrease in loans held for investment	(3,316)	11,148
Purchases of premises and equipment	(166)	(799)
Net cash (used in) provided by investing activities	(4,460)	14,273
Financing activities:
Increase in noninterest-bearing deposits	15,654	23,148
Increase (decrease) in savings deposits	29,900	(22,998)
Decrease in time deposits	(42,990)	(2,278)
Decrease in federal funds purchased, repurchase agreements and other borrowings, net	(639)	(699)
Increase in Federal Home Loan Bank advances	0	34,200
Repayment of Federal Home Loan Bank advances	0	(34,200)
Repayment and retirement of subordinated debt	(3,094)	0
Proceeds from Employee Stock Purchase Plan issuance	30	33
Cash dividends paid on common stock	(715)	(705)
Net cash used in financing activities	(1,854)	(3,499)
Net (decrease) increase in cash and cash equivalents	(4,149)	14,552
Cash and cash equivalents at beginning of period	140,044	78,759
Cash and cash equivalents at end of period	135,895	93,311
Cash payments for:
Interest	5,925	6,007
Supplemental schedule of noncash transactions
Unrealized gain (loss) on securities available-for-sale	2,106	(339)
Loans transferred to repossessed assets	$ 295	$ 865